Rapidly Hiring. They have a proprietary drug delivery platform known as the Technosphere. They deliver drugs through the lungs instead of injection or pills.
Afrezza their FDA approved drug is finally starting to generate sales after being fda approved years ago.
They are also working on several other products for 2020.
Huge accumulation range and due to very aggressive short sellers flooding the market with over 40 million additional shares over the years.
All of these short sales will eventually be pressured to rebuy rapidly driving up price. There are also warrants that were delayed and expire in July.
With the healthcare sector and biotech improving at a rapid pace, an effective product, all the catalysts are there.
Afrezza their FDA approved drug is finally starting to generate sales after being fda approved years ago.
They are also working on several other products for 2020.
Huge accumulation range and due to very aggressive short sellers flooding the market with over 40 million additional shares over the years.
All of these short sales will eventually be pressured to rebuy rapidly driving up price. There are also warrants that were delayed and expire in July.
With the healthcare sector and biotech improving at a rapid pace, an effective product, all the catalysts are there.
註釋
Target is still $8註釋
$10註釋
Update to $20免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。